← Back to Clinical Trials
Recruiting NCT06317181

NCT06317181 Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06317181
Status Recruiting
Phase
Sponsor Technische Universität Dresden
Condition Artificial Intelligence
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-04-01
Primary Completion 2025-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Collection of elastography dataCollection of ultrasonic raw data

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-04-01 with a primary completion date of 2025-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to test the performance of neuronal networks trained on ultrasonic raw Data (=radiofrequency data) for the assessment of liver diseases in patients undergoing a clinical ultrasound examination. The general feasibility is currently evaluated in a retrospective cohort. The main questions the study aims to answer are: * Can a neuronal network trained on RF Data perform equally good as elastography in the assessment of diffuse liver diseases? * Can a neuronal network trained on RF Data perform better than a neuronal network trained on b-mode images in the assessment of diffuse liver diseases? * Can a neuronal network trained on RF Data distinguish focal pathologies in the liver from healthy tissue? To answer these questions participants with a clinically indicated fibroscan will undergo: * a clinical elastography in Case ob suspected diffuse liver disease * a reliable ground truth (if normal ultrasound is not sufficient e.g. contrast enhanced ultrasound, biopsy, MRI or CT) in case of focal liver diseases, depending on the standard routine of the participating center * a clinical ultrasound examination during which b-mode images and the corresponding RF-Data sets are captured

Eligibility Criteria

Inclusion Criteria: * scheduled for an ultrasound investigation by an independent physician * signed declaration of consent Exclusion Criteria: * smaller interventions in the same liver during the last 2 Week (for example liver biopsy) * contrast enhanced ultrasound less than a day ago * major intervention at the liver (for example partial resection)

Contact & Investigator

Central Contact

Moritz Herzog, MD

✉ moritz.herzog@ukdd.de

📞 0049 351 458 11501

Principal Investigator

Moritz Herzog, MD

PRINCIPAL INVESTIGATOR

University Hospital Dresden

Frequently Asked Questions

Who can join the NCT06317181 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Artificial Intelligence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06317181 currently recruiting?

Yes, NCT06317181 is actively recruiting participants. Contact the research team at moritz.herzog@ukdd.de for enrollment information.

Where is the NCT06317181 trial being conducted?

This trial is being conducted at Dresden, Germany, Dresden, Germany, Halle, Germany, Leipzig, Germany.

Who is sponsoring the NCT06317181 clinical trial?

NCT06317181 is sponsored by Technische Universität Dresden. The principal investigator is Moritz Herzog, MD at University Hospital Dresden. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology